Conrad Santini

TL;DR: Novel, non-thiazolidinedione agonists for PPARγ and PPARδ that were identified by radioligand binding assays improve hyperglycemia and hypertriglyceridemia in vivo and are able to potentiate preadipocyte differentiation.

TL;DR: It is shown that treatment of insulin resistant db/db mice with the PPARδ agonist L‐165 041, at doses that had no effect on either glucose or triglycerides, raised total plasma cholesterol concentrations, suggesting both that PPAR δ is involved in the regulation of cholesterol metabolism in db/ db mice and that PP ARδ ligands could potentially have therapeutic value.

TL;DR: The design and synthesis of a novel class of 2,3-dihydrobenzofuran-2-carboxylic acids as highly potent and subtype-selective PPARalpha agonists are reported.

TL;DR: In this article, the instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds and compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.